Ningbo Menovo Pharmaceutical Co., Ltd. (SHA:603538)
China · Delayed Price · Currency is CNY 26.46
-0.74 (-2.72%)
Sep 10, 2026, 3:00 PM CST
SHA:603538 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 9,246 | 4,245 | 2,780 | 4,080 | 5,494 | 5,312 | |
Market Cap Growth | 66.71% | 52.68% | -31.86% | -25.74% | 3.44% | -4.38% |
Enterprise Value | 9,477 | 4,944 | 3,503 | 4,620 | 6,181 | 5,934 |
Last Close Price | 27.20 | 13.69 | 9.02 | 13.55 | 18.10 | 17.78 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 72.96 | 41.52 | 41.62 | 352.19 | 16.22 | 37.27 |
Forward PE | - | 27.68 | 13.31 | 23.46 | 18.90 | 24.70 |
PS Ratio | 5.49 | 2.82 | 2.03 | 3.35 | 3.77 | 4.22 |
PB Ratio | 3.06 | 1.73 | 1.21 | 1.87 | 2.53 | 2.69 |
P/TBV Ratio | 3.37 | 1.98 | 1.40 | 2.11 | 2.83 | 3.43 |
P/FCF Ratio | 159.46 | 93.33 | - | - | - | - |
P/OCF Ratio | 48.73 | 26.94 | 28.51 | 446.76 | 19.84 | 24.08 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 5.63 | 3.29 | 2.55 | 3.80 | 4.24 | 4.72 |
EV/EBITDA Ratio | 29.68 | 17.58 | 15.66 | 33.01 | 20.35 | 22.07 |
EV/EBIT Ratio | 51.94 | 33.16 | 37.47 | 175.24 | 30.09 | 34.92 |
EV/FCF Ratio | 163.44 | 108.70 | - | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.26 | 0.61 | 0.59 | 0.60 | 0.55 | 0.64 |
Debt / EBITDA Ratio | 2.44 | 5.29 | 5.90 | 8.99 | 3.92 | 4.69 |
Debt / FCF Ratio | 13.45 | 33.04 | - | - | - | - |
Net Debt / Equity Ratio | 0.05 | 0.24 | 0.26 | 0.26 | 0.09 | 0.24 |
Net Debt / EBITDA Ratio | 0.43 | 2.08 | 2.69 | 4.13 | 0.64 | 1.74 |
Net Debt / FCF Ratio | 2.36 | 12.85 | -7.35 | -2.75 | -0.66 | -1.51 |
Asset Turnover | 0.36 | 0.32 | 0.30 | 0.28 | 0.35 | 0.35 |
Inventory Turnover | 1.26 | 1.24 | 1.37 | 1.45 | 1.52 | 1.53 |
Quick Ratio | 0.76 | 0.85 | 0.71 | 0.80 | 0.90 | 0.90 |
Current Ratio | 1.43 | 1.44 | 1.24 | 1.28 | 1.39 | 1.48 |
Return on Equity (ROE) | 4.41% | 4.48% | 3.40% | 0.74% | 17.71% | 8.42% |
Return on Assets (ROA) | 2.43% | 1.96% | 1.29% | 0.37% | 3.05% | 2.98% |
Return on Invested Capital (ROIC) | 4.28% | 4.11% | 2.89% | 1.03% | 8.17% | 6.48% |
Return on Capital Employed (ROCE) | 5.70% | 4.60% | 3.00% | 0.90% | 6.70% | 6.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 1.26% | 2.41% | 2.40% | 0.28% | 6.17% | 2.68% |
FCF Yield | 0.63% | 1.07% | -2.94% | -5.16% | -5.36% | -5.82% |
Dividend Yield | 0.39% | 0.81% | 0.40% | 0.11% | 0.65% | 0.57% |
Payout Ratio | 41.58% | 25.33% | 34.00% | 511.34% | 14.76% | 9.71% |
Buyback Yield / Dilution | -0.94% | -0.92% | 7.02% | -1.93% | -6.91% | -3.49% |
Total Shareholder Return | -0.55% | -0.11% | 7.42% | -1.82% | -6.26% | -2.92% |